CDKN2A and cancer: The IFN-I pathway plays a key antiviral role, suggesting that CDKN2A-deficient MPM might particularly benefit from oncolytic viral therapy (11), a novel anti-cancer strategy that exploits oncolytic viruses, which preferentially replicate in cancer but not in normal cells (12).